Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading hours on Tuesday. $49.52 million flowed into the stock on the tick-up and $155.37 million flowed out of the stock on the tick-down, for a money net flow of $105.85 million out of the stock. Of all equities tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $0.05 for the day and closed at $125.35

Several equities research analysts have weighed in on ALXN shares. Leerink Swann restated a “buy” rating and issued a $216.00 target price (down from $217.00) on shares of Alexion Pharmaceuticals in a research note on Saturday, March 19th. Morgan Stanley restated a “buy” rating and issued a $195.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, April 1st. Vetr downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $161.67 target price for the company. in a research note on Monday, April 4th. Piper Jaffray Cos. restated a “buy” rating and issued a $212.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, April 5th. Finally, BMO Capital Markets started coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, April 6th. They issued a “market perform” rating and a $165.00 target price for the company. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $192.07.

The firm has a 50-day moving average price of $131.80 and a 200-day moving average price of $144.53. The firm has a market cap of $28.08 billion and a PE ratio of 189.64.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.13 by $0.02. The company had revenue of $701 million for the quarter, compared to analysts’ expectations of $710.98 million. Alexion Pharmaceuticals’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.28 EPS. Equities research analysts anticipate that Alexion Pharmaceuticals Inc. will post $5.05 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Martin Mackay sold 4,097 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $139.20, for a total transaction of $570,302.40. Following the completion of the transaction, the executive vice president now owns 42,706 shares in the company, valued at approximately $5,944,675.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John B. Moriarty sold 918 shares of the company’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in the company. Wetherby Asset Management Inc. increased its position in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Wetherby Asset Management Inc. now owns 10,211 shares of the biopharmaceutical company’s stock worth $1,948,000 after buying an additional 49 shares during the last quarter. LS Investment Advisors LLC increased its position in shares of Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 89 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 25,147 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 118 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Alexion Pharmaceuticals by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,722 shares of the biopharmaceutical company’s stock worth $2,808,000 after buying an additional 192 shares during the last quarter. Finally, RidgeWorth Capital Management LLC increased its position in shares of Alexion Pharmaceuticals by 0.3% in the fourth quarter. RidgeWorth Capital Management LLC now owns 150,951 shares of the biopharmaceutical company’s stock worth $28,794,000 after buying an additional 379 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.